IGC-502

IGC-502 is an investigational small molecule drug candidate being developed by IGC Pharma for the treatment of Alzheimer's disease. It functions as an inhibitor of c-Abl (Abelson murine leukemia viral oncogene homolog 1), a non-receptor tyrosine kinase that is often overactivated in neurodegenerative conditions. This overactivation is associated with the hyperphosphorylation of tau protein and the accumulation of amyloid-beta plaques, both of which are central to the pathology of Alzheimer's. By inhibiting c-Abl, IGC-502 aims to reduce these toxic protein aggregations and mitigate neuroinflammation, potentially offering a disease-modifying approach to slow cognitive decline. The candidate is currently in preclinical development.